Literature DB >> 2432087

Interactions of the platelets in paroxysmal nocturnal hemoglobinuria with complement. Relationship to defects in the regulation of complement and to platelet survival in vivo.

D V Devine, R S Siegel, W F Rosse.   

Abstract

The blood cells of patients with paroxysmal nocturnal hemoglobinuria (PNH) have abnormal interactions with complement. The activity of the alternative pathway C3 convertase on the platelets of 9 out of 19 patients with PNH was elevated. 10 patients had C3 convertase activity within the normal range even though 80-95% of their platelets lacked the complement regulatory protein decay accelerating factor (DAF) that is absent from the affected blood cells in PNH. PNH and normal platelets released factor H when C3 was bound to their surfaces. This may account for the apparent regulation of C3 convertase activity on platelets that lack DAF. The abnormal uptake of the membrane attack complex of complement by PNH III erythrocytes was not seen in PNH platelets. 111Indium-labeled platelet survival times were normal in five of eight patients, which suggests that the lack of the membrane attack complex defect results in normal platelet survival in PNH.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2432087      PMCID: PMC424006          DOI: 10.1172/JCI112773

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  35 in total

1.  STUDIES ON DESTRUCTION OF RED BLOOD CELLS. II. CHRONIC HEMOLYTIC ANEMIA WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: CERTAIN IMMUNOLOGICAL ASPECTS OF THE HEMOLYTIC MECHANISM WITH SPECIAL REFERENCE TO SERUM COMPLEMENT.

Authors:  T H Ham; J H Dingle
Journal:  J Clin Invest       Date:  1939-11       Impact factor: 14.808

2.  Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system.

Authors:  A Nicholson-Weller; J Burge; D T Fearon; P F Weller; K F Austen
Journal:  J Immunol       Date:  1982-07       Impact factor: 5.422

3.  Differences in the terminal steps of complement lysis of normal and paroxysmal nocturnal hemoglobinuria red cells.

Authors:  T A Rouault; W F Rosse; S Bell; J Shelburne
Journal:  Blood       Date:  1978-02       Impact factor: 22.113

4.  Increased enzymatic activity of the alternative pathway convertase when bound to the erythrocytes of paroxysmal nocturnal hemoglobinuria.

Authors:  C J Parker; P J Baker; W F Rosse
Journal:  J Clin Invest       Date:  1982-02       Impact factor: 14.808

5.  Two anticomplementary factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them.

Authors:  M Ballow; C G Cochrane
Journal:  J Immunol       Date:  1969-11       Impact factor: 5.422

6.  Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. I. The sensitivity of PNH red cells to lysis by complement and specific antibody.

Authors:  W F Rosse; J V Dacie
Journal:  J Clin Invest       Date:  1966-05       Impact factor: 14.808

7.  Human platelet-initiated formation and uptake of the C5-9 complex of human complement.

Authors:  T S Zimmerman; W P Kolb
Journal:  J Clin Invest       Date:  1976-01       Impact factor: 14.808

8.  Release of endogenous C3b inactivator from lymphocytes in response to triggering membrane receptors for beta 1H globulin.

Authors:  J D Lambris; N J Dobson; G D Ross
Journal:  J Exp Med       Date:  1980-12-01       Impact factor: 14.307

9.  Paroxysmal nocturnal hemoglobinuria: deficiency in factor H-like functions of the abnormal erythrocytes.

Authors:  M K Pangburn; R D Schreiber; J S Trombold; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1983-06-01       Impact factor: 14.307

10.  The human complement system in thrombin-mediated platelet function.

Authors:  M J Polley; R Nachman
Journal:  J Exp Med       Date:  1978-06-01       Impact factor: 14.307

View more
  8 in total

Review 1.  New insights into molecular pathogenesis of bone marrow failure in paroxysmal nocturnal hemoglobinuria.

Authors:  Tatsuya Kawaguchi; Hideki Nakakuma
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

Review 2.  Clinical manifestations of paroxysmal nocturnal hemoglobinuria: present state and future problems.

Authors:  Wendell F Rosse; Junichi Nishimura
Journal:  Int J Hematol       Date:  2003-02       Impact factor: 2.490

Review 3.  Management issues in paroxysmal nocturnal hemoglobinuria.

Authors:  Gabrielle Meyers; Charles J Parker
Journal:  Int J Hematol       Date:  2003-02       Impact factor: 2.490

4.  Identification of a novel mode of complement activation on stimulated platelets mediated by properdin and C3(H2O).

Authors:  Gurpanna Saggu; Claudio Cortes; Heather N Emch; Galia Ramirez; Randall G Worth; Viviana P Ferreira
Journal:  J Immunol       Date:  2013-05-15       Impact factor: 5.422

5.  Regulation of the activity of platelet-bound C3 convertase of the alternative pathway of complement by platelet factor H.

Authors:  D V Devine; W F Rosse
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

Review 6.  HUS and atypical HUS.

Authors:  T Sakari Jokiranta
Journal:  Blood       Date:  2017-04-17       Impact factor: 25.476

7.  Analysis of TET2 mutations in paroxysmal nocturnal hemoglobinuria (PNH).

Authors:  Camille Lobry; Ashish Bains; Leah B Zamechek; Sherif Ibrahim; Iannis Aifantis; David J Araten
Journal:  Exp Hematol Oncol       Date:  2019-08-21

Review 8.  Manipulation of cell surface macromolecules by flaviviruses.

Authors:  Robert Anderson
Journal:  Adv Virus Res       Date:  2003       Impact factor: 9.937

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.